Ultan McDermott
AstraZeneca (United Kingdom) · 591 works · 59,302 citations · h-index 82
Top works
- Signatures of mutational processes in human cancer
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- The principles and practice of oncology
- COSMIC: exploring the world's knowledge of somatic mutations in human cancer
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
- Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors
- Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling
- The repertoire of mutational signatures in human cancer
- Pan-cancer analysis of whole genomes
- Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
- Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
- The evolutionary history of lethal metastatic prostate cancer
- A Landscape of Pharmacogenomic Interactions in Cancer
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- Pharmacogenomic agreement between two cancer cell line data sets
- MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
- The evolutionary history of 2,658 cancers
- The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor